Who owns COGNITION THERAPEUTICS INC (CGTX)? Elite investor 13F holders
3 tracked elite investors reported holding COGNITION THERAPEUTICS INC as of 2026-06-30, including Renaissance Technologies LLC, Voss Capital, GAMCO. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | COGNITION THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 797281.00 USD | 693288.000000 | Shares | reduce | Original filing |
| Voss Capital | COGNITION THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 201250.00 USD | 175000.000000 | Shares | reduce | Original filing |
| GAMCO | COGNITION THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-12 00:00:00 | 23000.00 USD | 20000.000000 | Shares | hold | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.